drugset / Trial / NCT00647114

A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)

NCT00647114 ↗

Phase 1 Completed 41 enrolled Merck Sharp & Dohme LLC
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Treatment of patients with cancer types known to express the HER-2 and/or CEA tumor antigens.

Timeline

Start
2007-08
Primary completion
2008-09
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject V930 Vaccine 2.5 mg —
Subject V932 Vaccine 5e+08 vg —
Subject V932 Vaccine 5e+10 vg —

Indications